Timely Receipt of PCI in STEMI Up With Hospital Bypass Policy

Share this content:
Timely Receipt of PCI in STEMI Up With Hospital Bypass Policy
Timely Receipt of PCI in STEMI Up With Hospital Bypass Policy

TUESDAY, May 1, 2018 (HealthDay News) -- Adoption of policies allowing emergency medical services (EMS) to bypass non-percutaneous coronary intervention (PCI) capable hospitals for patients with ST-segment elevation myocardial infarction (STEMI) is associated with increased receipt of timely PCI, according to a study published online May 1 in Circulation: Cardiovascular Interventions.

Jacqueline L. Green, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues used data from six states with bypass policies (Delaware, Iowa, Maryland, North Carolina, Pennsylvania, and Massachusetts) matched to six states without bypass policies (South Carolina, Minnesota, Virginia, Texas, New York, and Connecticut) to examine receipt of reperfusion and receipt of timely PCI. Data were included for 19,287 patients at 379 sites across the 12 states.

The researchers found that patients from states with and without hospital destination policies were similar in age, gender, and comorbidities. Overall, 57.9 and 47.5 percent of patients, respectively, from states with hospital destination policies and states without hospital destination policies received primary PCI within their relevant guideline recommended time from first medical contact, after adjustment for patient- and state-level characteristics.

"Statewide adoption of STEMI hospital destination policies allowing EMS to bypass non-PCI capable facilities is associated with significantly faster treatment times for patients with STEMI," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »